Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Bone Rep. 2015 Jun 1;2:8–13. doi: 10.1016/j.bonr.2014.10.004

Figure 4.

Figure 4

Cycles to failure for each group. Alendronate (ALN) had fewer cycles to failure compared to the grand mean (p<0.01). Teriparatide (PTH) had more cycles to failure compared to the grand mean (p<0.01). Markers to the left represent individual sample data points. Box and whisker plots on the right show the minimum, maximum, mean, and 25th and 75th quartiles. Dashed line represents the grand mean.